Bavarian Nordic has commenced a Phase III trial of its chikungunya vaccine, CHIKV VLP, targeting the paediatric population ...

A landmark global modeling study reveals that more than 2.8 billion people in 104 countries are at risk of chikungunya, with ...

PARIS, June 13 (Xinhua) -- The first locally transmitted case of chikungunya in metropolitan France this year was confirmed on Wednesday in the town of La Crau, located in the southern department of ...

UK's medicine regulator said on Monday it has temporarily restricted the use of French vaccine maker Valneva's shot to treat ...

Climate change is reshaping Europe’s disease landscape, with tropical mosquito-borne illnesses like dengue and chikungunya ...

Results from the Phase II VLA1553-221 trial show that a full dose of Ixchiq demonstrated a 96.5% seroresponse rate in ...

Valneva reports positive six-month data for Ixchiq in children, supporting a full dose approach ahead of a Phase 3 trial set ...

COPENHAGEN, Denmark, June 12, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today the initiation of a Phase 3 clinical study of its single-dose, virus-like particle (VLP) chikungunya vaccine, CHIKV ...

Thanks to a clever modification of the baculovirus, vaccines can now be produced in insect cells more easily and cleaner.

The UK’s Medicines and Healthcare products Regulatory Agency said that following global reports of serious adverse events in ...

Sri Lanka is currently facing a grave public health crisis as the country has been witnessing a surge in the number of ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...